Dare Bioscience (NASDAQ:DARE) Posts Quarterly Earnings Results

Dare Bioscience (NASDAQ:DARE – Get Free Report) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05), Zacks reports. Dare Bioscience had a negative net margin of 803.80% and a negative return on equity of 748.30%. The firm had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $2.04 million.

Here are the key takeaways from Dare Bioscience’s conference call:

  • DARE to PLAY dispensing is planned to begin in November after product shipment to Medvantx. The company reported prescriptions from 182 office-based providers and across 48 states and Washington, D.C., though initial dispensing will be limited to 28 states.
  • Flora Sync LF5 has early signs of traction, with orders from 27 states, a first provider-office reorder, and a 4.9-star rating from approximately 25 reviews. Revenue so far was not material; Daré plans to add Amazon distribution in early 2027 and is developing two related products.
  • Daré expects data in 2027 from its Ovaprene phase III and DARE-HPV phase II programs. Grant funding continues to support development, including recent installments for DARE-LARC1 and the Ovaprene trial, while the company explores potential partnerships around its drug-delivery platform.
  • Commercial revenue remains very small and liquidity is limited: third-quarter revenue was about $48,000, cash was $11.5 million, and working capital was $3.2 million. The company reported a $3.2 million quarterly net loss, although that was lower than the prior-year loss.

Dare Bioscience Price Performance

NASDAQ:DARE opened at $0.58 on Tuesday. The firm has a market capitalization of $11.49 million, a price-to-earnings ratio of -0.83 and a beta of 1.11. Dare Bioscience has a 1 year low of $0.58 and a 1 year high of $3.78. The business has a 50 day simple moving average of $0.73 and a 200-day simple moving average of $1.50.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on DARE shares. Weiss Ratings downgraded Dare Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. HC Wainwright restated a “buy” rating on shares of Dare Bioscience in a report on Monday, August 17th. UBS Group set a $1.00 price objective on Dare Bioscience in a research note on Monday, September 14th. Benchmark reaffirmed a “buy” rating on shares of Dare Bioscience in a report on Monday, August 17th. Finally, Ladenburg Thalmann & Co. Inc. initiated coverage on Dare Bioscience in a report on Monday, October 26th. They set a “buy” rating and a $2.00 price objective on the stock. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Dare Bioscience currently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

View Our Latest Research Report on Dare Bioscience

Dare Bioscience Company Profile

(Get Free Report)

Daré Bioscience is a clinical-stage biopharmaceutical company focused on developing therapies and products for women’s health. Its work spans areas including contraception, vaginal health and sexual health, with an emphasis on addressing conditions and needs that have had limited treatment options. The company’s product candidates include Ovaprene, a hormone-free, monthly-use vaginal contraceptive, and investigational treatments for conditions such as female sexual arousal disorder. These candidates remain in development and are not approved for general use.

Read More

Earnings History for Dare Bioscience (NASDAQ:DARE)

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.